SCHEMBL4882387

SCHEMBL4882387

CCCC(=O)N1CCC(NC(=O)C(=O)c2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 13/20 0.69
TEAD1 P28347 1/20 0.50
HRH3 Q9Y5N1 2/20 0.47
SLC6A5 Q9Y345 3/20 0.46
NPY5R Q15761 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2730521 0.82 EPHX2 (1.00) EPHX2
SCHEMBL4883416 0.80 EPHX2 (0.67) EPHX2TEAD1NPY5R
SCHEMBL14086765 0.76 EPHX2 (0.62) EPHX2TEAD1HRH3
SCHEMBL27764410 0.76 EPHX2 (0.88) EPHX2
SCHEMBL4602598 0.75 EPHX2 (0.60) EPHX2TEAD1SLC6A5
SCHEMBL20041091 0.75 EPHX2 (0.80) EPHX2
SCHEMBL4881645 0.73 EPHX2 (0.48) EPHX2TEAD1SLC6A5
SCHEMBL4880073 0.73 LMNA (0.68) EPHX2
SCHEMBL2716590 0.72 EPHX2 (1.00) EPHX2
SCHEMBL4997428 0.71 EPHX2 (0.81) EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
WO-2008073623-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 EPHX2 2/4885TEAD1 1487/4885HRH3 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.